Cargando…

Targeting epigenetics as atherosclerosis treatment: an updated view

This review discusses the current developments on epigenetic inhibition as treatment for atherosclerosis. RECENT FINDINGS: The first phase III clinical trial targeting epigenetics in cardiovascular disease (CVD), BETonMACE, using the bromodomain inhibitor apabetalone (RVX-208) showed no significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neele, Annette E., Willemsen, Lisa, Chen, Hung-Jen, Dzobo, Kim E., de Winther, Menno P.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752220/ https://www.ncbi.nlm.nih.gov/pubmed/33027226 http://dx.doi.org/10.1097/MOL.0000000000000711

Ejemplares similares

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations
por: McIntosh, Craig S., et al.
Publicado: (2021)

ANGPTL3 as therapeutic target
por: Kersten, Sander
Publicado: (2021)

New algorithms for treating homozygous familial hypercholesterolemia
por: Tromp, Tycho R., et al.
Publicado: (2022)

Translating guidelines into practice via implementation science: an update in lipidology
por: Jones, Laney K., et al.
Publicado: (2022)

Angiopoietin-like 3 inhibition and the liver: less is more?
por: Oostveen, Reindert F., et al.
Publicado: (2023)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

The role of endocrine-disrupting phthalates and bisphenols in cardiometabolic disease: the evidence is mounting
por: Lucas, Andrew, et al.
Publicado: (2022)

HDL functionality in type 1 and type 2 diabetes: new insights
por: Chapman, M. John
Publicado: (2022)

Applying implementation science to improve care for familial hypercholesterolemia
por: Jones, Laney K., et al.
Publicado: (2022)

Macrophage subsets in atherosclerosis as defined by single‐cell technologies
por: Willemsen, Lisa, et al.
Publicado: (2020)

Tocar la cima del mundo
por: Weihenmayer, Erik

Repressing the repressor: Ezh2 mediates macrophage activation
por: Neele, Annette E., et al.
Publicado: (2018)

Type-I interferons in atherosclerosis
por: Chen, Hung-Jen, et al.
Publicado: (2019)

Gerald Ford y el futuro de la presidencia /
por: terHorst, Jerald F.
Publicado: (1976)

Erik Satie
por: Rey, Anne
Publicado: (1974)

Triptans in clinical practice: the basic scientist’s point of view
por: Buzzi, M. Gabriella
Publicado: (2001)

Social, economic, and policy implications of organ preservation advances
por: Ward, Alyssa, et al.
Publicado: (2018)

F©Ưsica recreativa /
por: Perelman, YakovI︡sidorovich, 1882-1942
Publicado: (1975)

Imaginación y crisis : modelo psicoanalítico-social de Erik H. Erikson
por: Delahanty, Guillermo

Diálogo con Erik Erikson
por: Evans, Richard I. (Richard Isadore), 1922-2015
Publicado: (1975)

Myeloid Ezh2 Deficiency Limits Atherosclerosis Development
por: Neele, Annette E., et al.
Publicado: (2021)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
por: Kline, Cassie, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
por: Majem, Margarita, et al.
Publicado: (2022)

Monocyte and Macrophage Lipid Accumulation Results in Down-Regulated Type-I Interferon Responses
por: Willemsen, Lisa, et al.
Publicado: (2022)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor
por: Anderson, Peter M., et al.
Publicado: (2022)

Grand Challenges in Gene and Epigenetic Editing for Neurologic Disease
por: Segal, David J.
Publicado: (2020)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

NOTCH regulation of the endothelial cell phenotype
por: Mack, Julia J., et al.
Publicado: (2018)

Preoperative laboratory testing in elderly patients
por: Lee, Kyung-Cheon, et al.
Publicado: (2021)

Prehospital stroke management and mobile stroke units
por: Fassbender, Klaus, et al.
Publicado: (2023)

Molecular MRI of Inflammation in Atherosclerosis
por: te Boekhorst, Bernard C., et al.
Publicado: (2011)

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uejelmdjt8vfhaqdvekshddp14